DNMT3B and Miyoshi myopathy: In addition, as mentioned above, a more recent study showed that Nanaomycin A significantly reduces the amount of MM CSC, thus suggesting that inhibition of DNMT3B using Nanaomycin A would be effective in targeting the CSC in MM (147).